Clinical data partnerships Koneksa is expanding through collaborations with proton therapy centers and Parkinson's observational studies, indicating a strong opportunity to offer measurement science and digital biomarker integration to oncology and neurodegenerative programs seeking real-world, patient-generated data.

New product launch The June 2026 Lodestar Intelligent Submission Software launch signals a push into streamlining trial data-to-submission workflows, presenting a sales angle to risk-adjusted, faster regulatory submissions and end-to-end data integration needs.

Executive hiring signals Recent VP of Clinical Development appointment and ongoing leadership changes suggest a company investing in scale and clinical strategy, creating openings for enterprise-level solutions around study design, measurement strategy, and cross-functional data interpretation services.

Evidence-based model Koneksa emphasizes disease biology grounded measurement strategies and integrated physiological, clinical, and digital signals, indicating opportunities to position advanced analytics, digital biomarkers, and standardization of endpoints for diverse therapeutic areas.

Mid-market growth With a mid-sized footprint and revenue in the mid tens of millions, Koneksa targets collaborations with biotech and pharma partners seeking specialty data science partners, suggesting tailoring scalable engagement models and flexible service tiers for sustainable growth.